Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$102.50M

Industries

Biotechnology,Clinical Trials,Health Care,Health Diagnostics

Founded date

Jan 1, 1997

Number Of Employee

51 - 100

Operating Status

Close

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.